Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Merck
Fuji
Farmers Insurance
UBS
Daiichi Sankyo
Harvard Business School
US Department of Justice
Express Scripts
QuintilesIMS

Generated: May 24, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,915,888

« Back to Dashboard

Which drugs does patent 8,915,888 protect, and when does it expire?

Patent 8,915,888 protects ADLYXIN and is included in one NDA.

This patent has twenty patent family members in sixteen countries.
Summary for Patent: 8,915,888
Title:Dosing and drive mechanism for drug delivery device
Abstract: The present invention relates to drive mechanisms suitable for use in drug delivery devices, in particular pen-type injectors, wherein a number of pre-set doses of medicinal product can be administered. In particular, the present invention relates to such drug delivery devices where a user may activate the drug delivery device.
Inventor(s): Boyd; Malcolm (Leamington Spa, GB), Letham; Richard (Kingston Upon Thames, GB), Plumptre; David (Worcerstershire, GB), Veasey; Robert (Leamington Spa, GB), May; James (Earlsdon, GB), Jones; Matthew (Warwickshire, GB), Ghazaros; Samuel (Bristol, GB)
Assignee: Sanofi-Aventis Deutschland GmbH (Frankfurt am Main, DE)
Application Number:12/466,581
Patent Claim Types:
see list of patent claims
Delivery; Device; Formulation; Compound; Dosage form; Use;

Drugs Protected by US Patent 8,915,888

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Sanofi-aventis Us ADLYXIN lixisenatide SOLUTION;SUBCUTANEOUS 208471-001 Jul 27, 2016 RX Yes Yes ➤ Sign Up ➤ Sign Up Y IMPROVEMENT IN GLYCEMIC CONTROL IN TYPE 2 DIABETES MELLITUS PATIENTS BY USE OF A PEN INJECTOR ➤ Sign Up
Sanofi-aventis Us ADLYXIN lixisenatide SOLUTION;SUBCUTANEOUS 208471-002 Jul 27, 2016 RX Yes Yes ➤ Sign Up ➤ Sign Up Y IMPROVEMENT IN GLYCEMIC CONTROL IN TYPE 2 DIABETES MELLITUS PATIENTS BY USE OF A PEN INJECTOR ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 8,915,888

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
06023961Nov 17, 2006

Non-Orange Book US Patents Family Members for Patent 8,915,888

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,855,388 Dosing and drive mechanism for drug delivery device ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chubb
Cerilliant
QuintilesIMS
US Department of Justice
Moodys
Covington
Fuji
McKinsey
US Army

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.